{
    "organizations": [],
    "uuid": "f28396f94b437163413f4e2f39e0af81992c2e61",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-regeneron-announces-approval-of-du/brief-regeneron-announces-approval-of-dupixent-in-japan-for-treatment-of-atopic-dermatitis-idUSFWN1PH0FX",
    "ord_in_thread": 0,
    "title": "BRIEF-Regeneron Announces Approval Of Dupixent (Dupilumab) In Japan For Treatment Of Atopic Dermatitis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - Regeneron Pharmaceuticals Inc:\n* REGENERON ANNOUNCES APPROVAL OF DUPIXENTÂ® (DUPILUMAB) IN JAPAN FOR THE TREATMENT OF ATOPIC DERMATITIS\n* REGENERON PHARMACEUTICALS - DUPIXENT IS BEING JOINTLY DEVELOPED BY CO, SANOFI UNDER A COLLABORATION AGREEMENT, & WILL BE COMMERCIALIZED IN JAPAN BY SANOFI Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-22T20:07:00.000+02:00",
    "crawled": "2018-01-23T17:48:21.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "regeneron",
        "announces",
        "approval",
        "dupilumab",
        "japan",
        "treatment",
        "atopic",
        "dermatitis",
        "regeneron",
        "pharmaceutical",
        "dupixent",
        "jointly",
        "developed",
        "co",
        "sanofi",
        "collaboration",
        "agreement",
        "commercialized",
        "japan",
        "sanofi",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}